${loserAccounts} been merged into ${winnerAccount}.
A recent audit found these accounts to be duplicative. Addresses, order history and Q-global ordering for both accounts are now accessible via the ${winnerAccount} account. If something isn’t right, please contact us.
This webinar focuses on the theoretical foundations of Bayley-4, and rationale for new concepts introduced to further refine its main purpose of identifying developmental delays. These concepts include a new scoring approach, Caregiver Report, reduced administration time, and refinement of content.
This presentation expands the conceptualization of attentional deficits to include Executive Functions and illustrates how a systemic process that aligns identification, assessment, and intervention can positively impact clients.
This webinar will familiarize participants with the administration, scoring, and interpretation of the Bayley Scales of Infant and Toddler Development – Fourth Edition (Bayley-4).
This session will illustrate the value of the SSIS SEL screening assessments and Classwide Intervention Program for educators focused on realizing a triple positive impact – increased SEL skills, decreased problem behaviors, and increased achievement in reading – for all elementary children school-wide.
Learn more about KABC-II NU, and the updates to the norms and standardization to ensure you are administering a culturally fair measure of cognitive ability assessment.
Now that you have evaluated and confirmed a student's ADHD diagnosis, what's next? What strategies, interventions, and supports are available to help you intervene in school? This webinar will highlight these and discuss their related integration within overall school practices.
This webinar discusses what an authentic reading assessment is and how the new DRA3 can help provide critical information to cultivate strong literacy skills within your students.
This webinar will explain specific areas of function that are delayed and intervention strategies appropriate for at least three of the clinical groups described in the Bayley-4 validity studies.